Abbott acquires Visiogen for cool $400 million
$400 million in cash has secured the acquisition of Visiogen for Abbott and secured the latter a next-generation accommodating IOL technology to help presbyopia in cataract patients.
$400 million in cash has secured the acquisition of Visiogen for Abbott and secured the latter a next-generation accommodating IOL technology to help presbyopia in cataract patients.
"Combining Visiogen's accommodating lens technology with Abbott's existing medical optics portfolio expands our ability to offer a diverse set of refractive options to our ophthalmic customers and the patients they serve."
Reza Zadno, founder, CEO and president of Visiogen, Inc. commented: "The global clinical results with Synchrony are extremely encouraging, and the opportunity to leverage Abbott Medical Optics' extensive commercialization infrastructure means that many more patients will benefit from this exciting advancement in cataract and presbyopia correction."
